Healthcare-Associated Infections in Ukraine and the Activity of 4-Thiazolidinone Derivatives Against Related Pathogens
NCT ID: NCT06508398
Last Updated: 2024-08-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
250 participants
OBSERVATIONAL
2017-09-01
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
What are the common pathogens responsible for HAIs in ICU patients? What is the antimicrobial and antifungal efficacy of 4-thiazolidinone derivatives against these pathogens?
Participants will have their clinical samples collected and analyzed for pathogen identification and susceptibility testing. The study will involve:
Collecting clinical data and samples from ICU patients Conducting microbiological and biochemical tests Screening new antimicrobial compounds for efficacy The study does not involve a comparison group as it focuses on observational data and laboratory analysis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Urogenital Infections in Women of Reproductive Age and the Activity of 4-Thiazolidinone Derivatives Against Pathogens
NCT06616168
Immunosuppression and Intensive Care Unit-acquired Multidrug-resistant Bacteria
NCT06652126
In Vitro Activity of Ceftolozane-tazobactam Against Contemporary Nosocomial Gram "-" Pathogens Isolated in Russia
NCT04679610
Antibacterial Effect of Zinc Oxide Nanoparticles on Acinetobacter Baumannii Isolated from Patients with Hospital Acquired Infections in Sohag University Hospitals, Egypt
NCT06628076
ICU-acquired Colonization and Infection Related to MDR in Immunocompromised Patients
NCT04043793
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
According to the study design, and analysis of the data of the CDC of Ukraine on the registration of HAIs cases in Ukraine during 2009-2020 was conducted. As a result, for the first time in Ukraine, the registration of HAIs for the last 12 years was analyzed; according to the results, an average of 4,759 ± 710 cases of HAIs have been registered annually. The analyzed materials give grounds to claim a significant underestimation of the incidence of HAIs in the country.
According to the results of a comprehensive, dynamic, clinical, and laboratory-instrumental examination of 250 patients of 4 local hospitals' ICU departments, and based on microbiological and epidemiological criteria, the corresponding diagnosis was confirmed in 205 patients. Among persons with HAIs, 46.8% were men, and 53.2% were women. Among all cases of HAIs, 24.9% were children (including 8.8% newborns), 64.9% - people aged 18-60 years, older adults (\> 60 years) were 10.2%. The most common nosologies were respiratory tract infections (36.6%) and urinary tract infections (34.1%). Most HAIs (58.6%) occurred from the 5th to the 14th day of hospital stay.
Three hundred eighty-nine biomaterials were taken, from which 309 strains of microorganisms were isolated, among which Gram-negative bacteria prevailed (51.5%), the species spectrum of which included representatives of 27 different species. Representatives of the genus Pseudomonas were the most isolated - 50 isolates, 16.2% of the total number of pathogens. Gram-positive microbiota is represented by 15 different species of pathogens, the most - members of the genus Staphylococcus - 52 isolates, which is 16.8% of the total number of pathogens. Among the fungi, 12 different species of pathogens were isolated, most of them Candida non-albicans - 20 isolates, which is 6.5% of the total number of pathogens.
For the first time in Ukraine, clinical cases caused by rare pathogens Raoultella (Klebsiella) terrigena and Vibrio metchikovii have been identified and described. Our reported cases were compared with the clinical cases described in the literature. It was shown that the isolate of R. terrigena has film-forming properties, more pronounced than the standard strain Raoutella terrigena ATCC 33257, and the rate of film formation exceeds the rate of film formation by staphylococci.
Analyzing the clinical case caused by Vibrio metchikovii, it should be noted that the most likely cause of infection is intraoperative microbial contamination of vascular prostheses.
Species identification of pathogens was performed using biochemical test systems (MIKRO-LA-TEST ErbaLachema, Czech Republic), using MALDI-TOF (conducted at the Department of Microbiology of the College of Medicine in Bydgoszcz, Poland) and for individual strains - 16sRNA-ID. The Identification score (index) of biochemical identification of cultures was \> = 95%, or \> = 99% for 87.4% of isolates (n=270). 50.8% of strains (n=157) had an atypicality index (Tin) of 0.25-0.49, i.e., these strains can be characterized as atypical. MALDI ID-score 95.5% of isolates (n=295) was \> = 2.0, ie showed good species identification, other isolates had ID score 1.7-1.9, which indicates generic identification. PCA analysis of Gram-negative rods of the genus Klebsiella allowed to divide them into 4 main clusters and showed significant similarity of isolates and, together with RAPD analysis, allowed to confirm the in-hospital transmission of pathogens. According to the results of 16S rRNA analysis, comparisons of Klebsiella pneumoniae isolates were performed, which testified to the common origin of the infection. Different identification methods established that a complete coincidence of results were recorded for 76.1% of strains (n=235). The highest identification accuracy is shown for 16sRNA analysis, but the speed is for MALDI-TOF.
The results of the antibiotic sensitivity showed that 62.8% (n=194) of isolates were MDR, 7.4% (n=23) were EDR, 28.8% (n=89) were not-MDR. 1% (n=3) strains were attributed to PDR: 2 - P.putida and 1 - P.aeruginosa. 33.8% (n=25) of the studied enterobacteria produced ESBL from another group of 47 studied isolates (83.9%) produced OXA-48, among which all isolates were MDR. The vast majority of fungal strains (82.9%) were resistant to fluconazole, which the most common choice of this drug can explain as empirical treatment of fungal infection.
Cultures of Achromobacter xylosoxidans (№ LMU-147) and Serratia marcescens (№ LMU-48) were isolated, for which their role in causing HAIs was proved. The isolated strains are classified as class IV pathogenicity, based on UA classification (US CDC classification - Biosafety level 1), but they can penetrate internal organs, more pronounced for serration. Candida utilis (LMU-127) is a low pathogenic strain that does not have invasive properties.
Fifty-five new synthesized thiazole derivatives were used to search for and study new chemical compounds with antibiotic activity. There was a pronounced antifungal effect in 3-\[5-(1H-Indol-3-ylmethylene)-4-oxo-2-thioxothiazolidin-3-yl\]-propanoic acid with a minimum inhibitory concentration against fungi of the genus Candida 25 μg/mL and a selective antimicrobial effect against Escherichia coli in 2-\[5-(1H-Indol-3-ylmethylene)-4-oxo-2-thioxothiazolidin-3-yl\]-ethanesulfonic acid with a similar effect (MIC=25 μg/mL). The most active against Staphylococcus aureus group was 2-(5-ylidene-4-oxo-2-thioxo-thiazolidin-3-yl)-succinimides with a terminal fragment in the C5 position.
For a 2-cyano-2- \[5- (ethoxymethylene) -4-oxo-3-phenyl-thiazolidin-2-ylidene\] -N- (o-tolyl) acetamide derivative which does not contain a phenyleneamine or benzylidene moiety in the structure at position C5 position of the thiazolidone nucleus showed the highest activity against the multidrug-resistant clinical strain of Pseudomonas aeruginosa.
A laboratory animal model studied the immunotoxic/allergenic/acute toxic effect of the \"leader compound\" with antimicrobial activity. No immunotoxic and allergenic effects were found, but there is a moderate anti-inflammatory effect. Against the background of an increase in the absolute number of CD3 T-lymphocytes by 21.46%, a slight decrease in the quantitative level of CD22 B-lymphocytes (by 1.98%) was recorded. Activation of the suppressor link caused some decrease in the immunoregulatory index (indicator is unreliable).
The effect of the test substance on the level of immunoglobulins and interleukins of laboratory animals showed a significant decrease in IgA by 21.4% (p \<0.05) and an increase in IgG by 21.2%. Thus, there was an increase in the activity of the phagocytic system in terms of the growth of the phagocytic number and absorption properties of neutrophils. The selectivity of such biological activity may be useful in the treatment of some immunopathological conditions.
The identified effects accompanying antifungal activity indicate the prospects for further study of the \"drug-like molecule\" with polytargetative action.
The analysis of the HAIs prevalence, their registration, the state of specific diagnostics, comparison of modern methods of identification of microbial isolates from clinical material indicates the need to increase the level of microbiological research, implementation of a standardized registration system, and research of nosocomial infections with potentially adverse health effects.
According to the thesis results and research of isolates\' biological properties, the corresponding strains were deposited in the Depository of the Institute of Microbiology and Virology of the National Academy of Sciences of Ukraine.
Based on the research, 2 utility model patents were issued. In addition, molecular docking studies have shown that the \"leader compound\" 7-(3,4-Dimethoxyphenyl)-5-methyl-3H-thiazolo\[4,5-b\]pyridin-2-one has shown good binding to selected protein targets compared to the reference N21 inhibitor and ciprofloxacin.
Keywords Healthcare-Associated Infections (HAIs), nosocomial infections, antimicrobial resistance, antibiotic resistance, device-associated pathogens, antimicrobial activity, antifungal activity, 4-thiazolidinones, thiazoles, cellular immunity, immunotropic action, guinea pigs, MALDI, rare pathogens.
Publications. According to the thesis materials, 10 articles were published, including 8 articles indexed in the journals Web of Science and/or Scopus, article in the Ukrainian professional journal, 1 article in a non-professional journal.
The work results were presented at 17 conferences, including in the form of an oral report at 3 international conferences outside Ukraine and 1 conference in Ukraine.
Based on the work results, 2 utility model patents and 3 certificates of initial deposition of the microorganism strain were published.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ICU Patients with Healthcare-Associated Infections
This group consists of patients admitted to the Intensive Care Units (ICUs) in Lviv hospitals who are diagnosed with healthcare-associated infections (HAIs). The study involves collecting clinical samples, including blood, urine, sputum, bronchoalveolar lavage, wound swabs, and oropharyngeal/nasopharyngeal swabs, to identify bacterial and fungal pathogens and analyze their antimicrobial resistance profiles. The data collected will be used to evaluate the effectiveness of new 4-thiazolidinone derivatives against these pathogens.
Microbiological Diagnostic Testing
This study involves microbiological diagnostic testing of clinical samples collected from ICU patients diagnosed with healthcare-associated infections (HAIs). The intervention includes:
Sample Collection: Blood, urine, sputum, bronchoalveolar lavage, wound swabs, and oropharyngeal/nasopharyngeal swabs.
Pathogen Identification: Using biochemical tests, MALDI-TOF mass spectrometry, and 16S rRNA sequencing to identify bacterial and fungal pathogens.
Antimicrobial Susceptibility Testing: Determining the resistance profiles of the identified pathogens to various antimicrobial agents.
Evaluation of New Compounds: Testing the antimicrobial efficacy of new 4-thiazolidinone derivatives against isolated pathogens.
This comprehensive approach aims to enhance the understanding of pathogen distribution and resistance patterns in HAIs.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Microbiological Diagnostic Testing
This study involves microbiological diagnostic testing of clinical samples collected from ICU patients diagnosed with healthcare-associated infections (HAIs). The intervention includes:
Sample Collection: Blood, urine, sputum, bronchoalveolar lavage, wound swabs, and oropharyngeal/nasopharyngeal swabs.
Pathogen Identification: Using biochemical tests, MALDI-TOF mass spectrometry, and 16S rRNA sequencing to identify bacterial and fungal pathogens.
Antimicrobial Susceptibility Testing: Determining the resistance profiles of the identified pathogens to various antimicrobial agents.
Evaluation of New Compounds: Testing the antimicrobial efficacy of new 4-thiazolidinone derivatives against isolated pathogens.
This comprehensive approach aims to enhance the understanding of pathogen distribution and resistance patterns in HAIs.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Danylo Halytsky Lviv National Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yulian Konechnyi, PhD
Role: PRINCIPAL_INVESTIGATOR
Danylo Halytsky Lviv National Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Danylo Halytsky Lviv National Medical University
Lviv, Lviv Oblast, Ukraine
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Konechnyi Y, Khorkavyi Y, Ivanchuk K, Kobza I, Sekowska A, Korniychuk O. Vibrio metschnikovii: Current state of knowledge and discussion of recently identified clinical case. Clin Case Rep. 2021 Mar 4;9(4):2236-2244. doi: 10.1002/ccr3.3999. eCollection 2021 Apr.
Lekhniuk N, Fesenko U, Pidhirnyi Y, Sekowska A, Korniychuk O, Konechnyi Y. Raoultella terrigena: Current state of knowledge, after two recently identified clinical cases in Eastern Europe. Clin Case Rep. 2021 Mar 31;9(5):e04089. doi: 10.1002/ccr3.4089. eCollection 2021 May.
Sekowska A, Konechnyi Y, Gospodarek-Komkowska E. Klebsiella pneumoniae infection in a liver transplant patient: A case report and review of the literature. Indian J Med Microbiol. 2021 Oct-Dec;39(4):548-551. doi: 10.1016/j.ijmmb.2021.07.001. Epub 2021 Jul 24.
Khamitova capital A, Cyrillic, Berillo D, Lozynskyi A, Konechnyi Y, Mural D, Georgiyants V, Lesyk R. Thiadiazole and Thiazole Derivatives as Potential Antimicrobial Agents. Mini Rev Med Chem. 2024;24(5):531-545. doi: 10.2174/1389557523666230713115947.
Konechnyi Y, Panas M, Tymchuk I, Havur O, Borysiuk O, Hubytska I, Zhurakhivska L, Konechna R, Korniychuk O. Epidemiological and microbiological aspects of healthcare-associated infections in Ukraine during the 2009-2019 period. Przegl Epidemiol. 2021;75(1):86-95. doi: 10.32394/pe.75.09.
Konechnyi Y, Rumynska T, Yushyn I, Holota S, Turkina V, Ryviuk Rydel M, Sekowska A, Salyha Y, Korniychuk O, Lesyk R. A New 4-Thiazolidinone Derivative (Les-6490) as a Gut Microbiota Modulator: Antimicrobial and Prebiotic Perspectives. Antibiotics (Basel). 2024 Mar 22;13(4):291. doi: 10.3390/antibiotics13040291.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020.02/0035
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
FEMS-GO-2020-195
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
Ministry of Health of Ukraine
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
Ministry of Health of Ukraine
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
06/25/2018, N6; 06/22/2020, N6
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.